106 related articles for article (PubMed ID: 2471879)
1. Mediation of the cardiac effects of forskolin by specific binding sites.
Schmidt K; Kukovetz WR
J Cardiovasc Pharmacol; 1989 Mar; 13(3):353-60. PubMed ID: 2471879
[TBL] [Abstract][Full Text] [Related]
2. Binding of [14,15-3H]14,15-dihydroforskolin to rat liver membranes: comparison with the stimulatory effect of forskolin on adenylate cyclase.
Schmidt K; Baer HP; Shariff A; Ayer WA; Browne L
Can J Physiol Pharmacol; 1987 May; 65(5):803-9. PubMed ID: 3621043
[TBL] [Abstract][Full Text] [Related]
3. Activation of adenylate cyclase and inhibition of glucose transport in rat adipocytes by forskolin analogues: structural determinants for distinct sites of action.
Joost HG; Habberfield AD; Simpson IA; Laurenza A; Seamon KB
Mol Pharmacol; 1988 Apr; 33(4):449-53. PubMed ID: 3357486
[TBL] [Abstract][Full Text] [Related]
4. Characterization of [3H]forskolin binding sites in the iris-ciliary body of the albino rabbit.
Goldman ME; Mallorga P; Pettibone DJ; Sugrue MF
Life Sci; 1988; 42(13):1307-14. PubMed ID: 3352456
[TBL] [Abstract][Full Text] [Related]
5. [3H]forskolin binding to cardiac adenylate cyclase in guinea pigs chronically infused with isoproterenol.
McMartin L; Summers RJ
Life Sci; 1995; 57(11):1039-49. PubMed ID: 7658911
[TBL] [Abstract][Full Text] [Related]
6. Cardiac adenylate cyclase activity, positive chronotropic and inotropic effects of forskolin analogs with either low, medium or high binding site affinity.
Hubbard JW; Conway PG; Nordstrom LC; Hartman HB; Lebedinsky Y; O'Malley GJ; Kosley RW
J Pharmacol Exp Ther; 1991 Feb; 256(2):621-7. PubMed ID: 1993999
[TBL] [Abstract][Full Text] [Related]
7. Differential forskolin activation of rat heart and lung adenylate cyclase. Dependence on membrane-protein interactions.
Jackman GP; Bobik A
Biochem Pharmacol; 1989 Apr; 38(7):1091-5. PubMed ID: 2706008
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a single forskolin-binding site in rat adipocyte membrane. Studies of [14,15-3H]dihydroforskolin binding and adenylate cyclase activation.
Ho RJ; Shi QH
J Biol Chem; 1984 Jun; 259(12):7630-6. PubMed ID: 6539776
[TBL] [Abstract][Full Text] [Related]
9. Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog.
Calderone A; Bouvier M; Li K; Juneau C; de Champlain J; Rouleau JL
Circ Res; 1991 Aug; 69(2):332-43. PubMed ID: 1650296
[TBL] [Abstract][Full Text] [Related]
10. Characterization of forskolin binding sites in rat brain membranes using [14,15-3H]14,15-dihydroforskolin as a ligand.
Schmidt K; Munshi R; Baer HP
Naunyn Schmiedebergs Arch Pharmacol; 1984 Feb; 325(2):153-8. PubMed ID: 6538936
[TBL] [Abstract][Full Text] [Related]
11. Binding of [3H]forskolin to solubilized preparations of adenylate cyclase.
Nelson CA; Seamon KB
Life Sci; 1988; 42(14):1375-83. PubMed ID: 3352459
[TBL] [Abstract][Full Text] [Related]
12. Forskolin-mediated activation of cardiac, liver and lung adenylate cyclase in the rat. Relation to [3H]forskolin binding sites.
Jackman GP; Bobik A
Biochem Pharmacol; 1986 Jul; 35(13):2247-51. PubMed ID: 3729979
[TBL] [Abstract][Full Text] [Related]
13. Inotropic, chronotropic and coronary vasodilator potency of forskolin.
Vaden SL; Adams HR
Eur J Pharmacol; 1985 Nov; 118(1-2):131-7. PubMed ID: 3002808
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on [3H]SCH23390 and [3H]forskolin binding in rat striatum.
Norman AB; Wachendorf TJ; Sanberg PR
Life Sci; 1989; 44(13):831-6. PubMed ID: 2648096
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of [3H]forskolin binding by Gpp[NH]p may reflect adenylate cyclase coupling to Gi.
Garcia-Jiménez A; Cowburn RF; Winblad B; Fastbom J
Neuroreport; 1999 Aug; 10(11):2423-7. PubMed ID: 10439475
[TBL] [Abstract][Full Text] [Related]
16. Effects of guanine nucleotides and divalent cations on forskolin activation of rabbit luteal adenylyl cyclase: evidence for the existence of an inhibitory guanine nucleotide-binding regulatory component.
Abramowitz J; Campbell AR
Endocrinology; 1984 Jun; 114(6):1955-62. PubMed ID: 6327229
[TBL] [Abstract][Full Text] [Related]
17. Evidence that forskolin activates turkey erythrocyte adenylate cyclase through a noncatalytic site.
Morris SA; Bilezikian JP
Arch Biochem Biophys; 1983 Feb; 220(2):628-36. PubMed ID: 6297407
[TBL] [Abstract][Full Text] [Related]
18. Stimulatory and inhibitory regulation of myocardial adenylate cyclase by 5'-guanylyl-imidodiphosphate.
Steinberg SF; Chow YK; Bilezikian JP
Biochem Pharmacol; 1987 Mar; 36(5):757-64. PubMed ID: 3103629
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and inotropic potential of forskolin in the human heart.
Bristow MR; Ginsburg R; Strosberg A; Montgomery W; Minobe W
J Clin Invest; 1984 Jul; 74(1):212-23. PubMed ID: 6330174
[TBL] [Abstract][Full Text] [Related]
20. Forskolin stabilizes a functionally coupled state between activated guanine nucleotide-binding stimulatory regulatory protein, Ns, and catalytic protein of adenylate cyclase system in rat erythrocytes.
Yamashita A; Kurokawa T; Higashi K; Dan'ura T; Ishibashi S
Biochem Biophys Res Commun; 1986 May; 137(1):190-4. PubMed ID: 3087354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
